• 1
    Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics: the MACH1 study. Helicobacter 1996; 1: 13844.
  • 2
    Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 70312.
  • 3
    Veldhuyzen Van Zanten SJO, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 28995.
  • 4
    Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with one-week triple therapies. Gastroenterology 1999; 116: 24853.
  • 5
    Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 7983.
  • 6
    The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 813.
  • 7
    Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 22343.
  • 8
    Leung WK, Graham DY. Rescue therapy for Helicobacter pylori. Curr Treat Options Gastroenterol 2002; 5: 1338.
  • 9
    Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection — the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 10
    O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multi-center study. Aliment Pharmacol Ther 2003; 17: 41520.
  • 11
    Mantzaris GJ, Petraki K, Archavlis E, et al. Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. Eur J Gastroenterol Hepatol 2002; 14: 123743.
  • 12
    Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE study. Gastroenterology 2002; 123: 17639.
  • 13
    Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 133343.
  • 14
    Georgopoulos DS, Ladas SD, Karatapanis S, et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 2002; 16: 56975.
  • 15
    Gisbert JP, Gisbert JL, Marcos S, Garcia Gravalos R, Carpio D, Pajares JM. Seven-day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther 1999; 13: 13116.
  • 16
    Zullo A, Hassan C, Campo SMA, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001; 15: 11937.
  • 17
    Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 3116.
  • 18
    Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskava Z. Furazolidone-based triple ‘rescue therapy’ vs. quadruple ‘rescue therapy’ for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 127782.
  • 19
    Huang JQ, Hunt RH. Treatment after failure: the problem of ‘non-responders’. Gut 1999; 45: 1405.
  • 20
    Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003; 8: 904.
  • 21
    Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 2326.
  • 22
    Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther 2000; 14: 13358.
  • 23
    Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002; 7: 22531.
  • 24
    Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001; 17: 3944.
  • 25
    Monteiro LM, Mégraud F. Microbiological aspects of antibiotic resistant Helicobacter pylori strains. Ital J Gastroenterol Hepatol 1998; 30(Suppl. 3): S32933.
  • 26
    National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing (NEELS). Twelfth Informational Supplement M100-S12. Wayne PA: National Committee for Clinical Laboratory Standards, 2002.
  • 27
    Goh KL. Update on indications for treatment of Helicobacter pylori (including Maastricht 2). Curr Opin Gastroenterol 2001; 17(Suppl. 1): S436.
  • 28
    Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 2003; 18: 34753.
  • 29
    Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 6876.
  • 30
    Fakheri H, Malekzadeh R, Merat S, et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 4116.
  • 31
    Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003; 8: 3079.
  • 32
    Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 3109.
  • 33
    Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter 2002; 7: 99104.
  • 34
    Borody TJ, George LL, Brandl S, et al. Helicobacter pylori eradication with doxycycline–metronidazole–bismuth subcitrate triple therapy. Scand J Gastroenterol 1992; 27: 2814.
  • 35
    Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 10612.
  • 36
    Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 53841.
  • 37
    Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 55360.
  • 38
    Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003; 18: 62733.
  • 39
    Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 7115.
  • 40
    Kim JJ, Lim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 2003; 8: 2026.